At iama therapeutics, we strive to develop innovative medicines for brain disorders with unmet medical needs.

parallax background

We push the boundaries of neuroscience drug discovery to develop new medicines and make a difference in the lives of individuals suffering from brain disorders.

We seek to couple emerging advances in drug discovery and neurobiology to build a leading, next-generation neuroscience pipeline.


Scientific strategy

We have developed a platform to identify and advance diverse classes of small molecules to selectively inhibit the sodium-potassium chloride cotransporter (NKCC1) and other therapeutic targets relevant to treating central nervous system disorders.



Working at Iama therapeutics

Our core values root in excellence, innovation, integrity, equality, respect for diversity, and sustainability of our future generations.


latest news

26 Luglio 2022

Business Wire – 27/07/22

IAMA Therapeutics Announces Initiation of Preclinical Development Studies in Drug-resistant Epilepsy Under a Service Agreement with Psychogenics
29 Giugno 2022

Business Wire – 29/06/22

IAMA Therapeutics to Present Preclinical Data of Selective NKCC1-Inhibitors at the International Neuroscience Conference FENS Forum 2022
24 Maggio 2022

Business Wire – 24/05/22

IAMA Therapeutics Announces Oral Presentation at the XXVII EFMC International Symposium on Medicinal Chemistry